Erdafixen 4mg Tablet (Erdafitinib) – Long Product Description

Erdafixen 4mg Tablet (Erdafitinib) is a prescription targeted anti-cancer medicine manufactured by Everest Pharmaceuticals Ltd. It contains Erdafitinib 4mg, a fibroblast growth factor receptor (FGFR) inhibitor used to treat certain advanced cancers with specific FGFR2 or FGFR3 genetic alterations. Erdafixen is primarily indicated for the treatment of locally advanced or metastatic urothelial carcinoma (bladder cancer) in eligible adult patients whose cancer has progressed despite previous treatment. By targeting abnormal FGFR signaling, Erdafitinib helps slow tumor growth and improves disease control in patients with FGFR mutation-positive cancers.

Each pack of Erdafixen 4mg Tablet contains 28 tablets, providing a convenient oral treatment option for continuous therapy under the supervision of an oncologist. Before starting treatment, patients should undergo FDA-approved or validated FGFR genetic testing to confirm eligibility for Erdafitinib therapy.

How Erdafixen 4mg Tablet Works

Erdafitinib is a targeted FGFR tyrosine kinase inhibitor that blocks the activity of FGFR1, FGFR2, FGFR3, and FGFR4 proteins. In certain cancers, mutations or fusions involving FGFR genes lead to uncontrolled cell growth and tumor progression. Erdafitinib inhibits these abnormal signaling pathways, slowing cancer cell proliferation and promoting programmed cell death (apoptosis).

Because it targets a specific genetic alteration rather than rapidly dividing cells in general, Erdafitinib offers a more personalized treatment approach for eligible patients.

Uses of Erdafixen 4mg Tablet

Erdafixen 4mg Tablet is indicated for:

• Treatment of locally advanced urothelial carcinoma with susceptible FGFR alterations.
• Treatment of metastatic urothelial (bladder) cancer with confirmed FGFR2 or FGFR3 genetic alterations.
• Patients whose disease has progressed following previous systemic therapy.
• Targeted treatment based on molecular genetic testing.

Treatment should only be initiated after confirmation of an eligible FGFR2 or FGFR3 mutation or fusion.

Benefits of Erdafixen 4mg Tablet

Erdafixen offers several important therapeutic benefits, including:

• Specifically targets cancers with FGFR genetic alterations.
• Helps slow the progression of advanced bladder cancer.
• Oral tablet for convenient daily administration.
• Personalized targeted therapy based on molecular testing.
• May improve progression-free survival and overall response in eligible patients.
• Manufactured by Everest Pharmaceuticals Ltd., a trusted pharmaceutical company.

Dosage and Administration

Erdafixen 4mg Tablet should be taken exactly as prescribed by an oncologist. It is usually taken once daily, with or without food. The dose may be adjusted based on serum phosphate levels, treatment response, and side effects.

Patients should swallow the tablets whole with water and should not crush, split, or chew them unless instructed by their healthcare provider.

Regular monitoring of serum phosphate, kidney function, liver function, eye health, and other laboratory parameters is essential throughout treatment.

Possible Side Effects

Like all targeted cancer medicines, Erdafixen may cause side effects.

Common side effects include:

• Elevated phosphate levels (hyperphosphatemia)
• Dry mouth
• Diarrhea
• Fatigue
• Nail disorders
• Dry skin
• Hair loss
• Mouth sores
• Loss of appetite
• Altered taste sensation

Serious side effects may include:

• Eye disorders, including central serous retinopathy (CSR) or retinal pigment epithelial detachment (RPED)
• Vision changes
• Severe hyperphosphatemia
• Liver function abnormalities
• Severe skin reactions
• Allergic reactions

Patients should immediately report blurred vision, eye pain, visual disturbances, severe skin reactions, or persistent swelling to their healthcare provider.

Precautions and Warnings

Before taking Erdafixen 4mg Tablet, inform your doctor if you have:

• Eye disease or vision problems
• Kidney disease
• Liver disease
• High phosphate levels
• Pregnancy or plans to become pregnant
• Breastfeeding

Regular ophthalmologic examinations are recommended before and during treatment because Erdafitinib may affect the retina and vision.

Women and men of reproductive potential should use effective contraception during treatment and for the recommended period after the final dose.

Storage Information

Store Erdafixen 4mg Tablets at room temperature below 30°C, protected from heat, moisture, and direct sunlight. Keep the tablets in their original packaging and out of the reach of children.

Why Buy Erdafixen 4mg Tablet from MedicineWalyDost?

At MedicineWalyDost, we provide genuine targeted oncology medicines sourced from trusted pharmaceutical manufacturers. Erdafixen 4mg Tablet by Everest Pharmaceuticals is available with reliable nationwide delivery across Pakistan for oncology hospitals, clinics, and eligible patients requiring precision cancer therapy.

When you order from MedicineWalyDost, you receive:

• Genuine targeted oncology medicines
• Competitive prices
• Nationwide delivery across Pakistan
• Secure packaging
• Professional customer support
• Assistance with medicine availability and ordering

Note: A valid prescription from a qualified oncologist is required before purchasing Erdafixen 4mg Tablet.

---

Frequently Asked Questions (FAQs)

What is Erdafixen 4mg Tablet used for?

Erdafixen 4mg Tablet is used to treat locally advanced or metastatic urothelial (bladder) cancer in adults with FGFR2 or FGFR3 genetic alterations.

Who manufactures Erdafixen 4mg Tablet?

Erdafixen 4mg Tablet is manufactured by Everest Pharmaceuticals Ltd.

What is the pack size?

Each pack contains 28 tablets.

Is genetic testing required before treatment?

Yes. A confirmed FGFR2 or FGFR3 genetic alteration is required before starting Erdafitinib because the medicine specifically targets these mutations.

Is a prescription required?

Yes. Erdafixen 4mg Tablet is a prescription-only targeted oncology medicine and should only be used under the supervision of a qualified oncologist.